Literature DB >> 2548528

Chromatin structure and transcriptional regulation of human papillomavirus type 18 DNA in HeLa cells.

F Rösl1, E M Westphal, H zur Hausen.   

Abstract

Mapping analysis of the nucleosomal organization of integrated human papillomavirus type 18 (HPV18) DNA in HeLa cells reveals a very prominent nuclease-hypersensitive site within the viral noncoding regulatory region that harbors transcriptional control sequences and coincides with most of the 5' ends of the cytoplasmic early mRNAs. Moreover, it is shown that the conserved coamplified 5' cellular flank, common to all HPV18 copies in HeLa cells and located close to the virus-cell integration site, also contains several distinct hypersensitive sites, accessible not only to DNase I but also to restriction enzymes. Nuclear run-on analysis in isolated HeLa nuclei demonstrates the occurrence of nascent transcripts covering the cellular flank (the late and the viral noncoding regulatory region), indicating that a cellular promoter, marked by the hypersensitive sites, cooperates with the viral control region in generating the HPV18 transcripts. Cycloheximide treatment of HeLa cells results in a reduction of the cytoplasmic steady-state level of the 3.5-kb mRNA corresponding to the viral E6, E7, and parts of the E1 open reading frames (ORFs), whereas the expression of the 1.6-kb transcript corresponding only to the E6 and E7 ORFs is not influenced. Nuclear run-on analysis carried out after the cycloheximide chase reveals that the distribution of nascent transcripts spanning the viral E6, E7, and parts of the E1 region is substantially decreased. In contrast to this finding, an even, pronounced increase of the elongation rate of those transcripts, which cover the cellular flank, the late and the viral noncoding regulatory region was noted indicating a different involvement of regulatory factors in the activity of both promoters.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548528     DOI: 10.1002/mc.2940020205

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  8 in total

1.  The Nuclear DNA Sensor IFI16 Acts as a Restriction Factor for Human Papillomavirus Replication through Epigenetic Modifications of the Viral Promoters.

Authors:  Irene Lo Cigno; Marco De Andrea; Cinzia Borgogna; Silvia Albertini; Manuela M Landini; Alberto Peretti; Karen E Johnson; Bala Chandran; Santo Landolfo; Marisa Gariglio
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Episomal amplification or chromosomal integration of the viral genome: alternative pathways in hamster polyomavirus-induced lymphomas.

Authors:  S Mazur; J Feunteun; C de La Roche Saint André
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

3.  Disturbance of tumor necrosis factor alpha-mediated beta interferon signaling in cervical carcinoma cells.

Authors:  Anastasia Bachmann; Brigitte Hanke; Rainer Zawatzky; Ubaldo Soto; Jan van Riggelen; Harald zur Hausen; Frank Rösl
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number.

Authors:  P Finzer; M Stöhr; N Seibert; F Rösl
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-27       Impact factor: 4.553

Review 5.  Papillomavirus interaction with cellular chromatin.

Authors:  Jianxin You
Journal:  Biochim Biophys Acta       Date:  2009-09-26

Review 6.  Therapeutics Targeting Protein Acetylation Perturb Latency of Human Viruses.

Authors:  Ryan J Conrad; Melanie Ott
Journal:  ACS Chem Biol       Date:  2016-02-15       Impact factor: 5.100

7.  Extinction of the HPV18 upstream regulatory region in cervical carcinoma cells after fusion with non-tumorigenic human keratinocytes under non-selective conditions.

Authors:  F Rösl; T Achtstätter; T Bauknecht; K J Hutter; G Futterman; H zur Hausen
Journal:  EMBO J       Date:  1991-06       Impact factor: 11.598

8.  Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer.

Authors:  Edgar Grinstein; Peter Wernet; Peter J F Snijders; Frank Rösl; Inge Weinert; Wentao Jia; Regine Kraft; Christiane Schewe; Michael Schwabe; Steffen Hauptmann; Manfred Dietel; Chris J L M Meijer; Hans-Dieter Royer
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.